At the University Hospital Marburg, following the successful individual treatment of a single patient (32), we conducted a non-randomized phase-II trial of the JAK1/2-Inhibitor Ruxolitinib in critically ill COVID-19 patients requiring mechanical ventilation (20). The gene discussed is JAK1; the disease is COVID-19.